![](/images/graphics-bg.png)
PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma
Joint Authors
Bai, Hua
Zhu, Yudi
Xu, Peipei
Chen, Bing
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-06-10
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Multiple myeloma (MM) is a devastating cancer with a highly heterogeneous outcome.
Because of the heterogeneity of myeloma cells, risk stratification is important for making therapeutic regimens.
Nevertheless, no immunohistochemical predictive and prognostic marker has been constructed yet.
In the present study, we explored the prognostic value of proteolipid protein 2 (PLP2) in MM patients using immunohistochemistry (IHC).
We assessed PLP2 expression in bone marrow (BM) biopsy specimens obtained from 87 newly diagnosed MM (NDMM) patients.
Correlations between PLP2 expression and clinicopathological features were analyzed.
PLP2 expression was present in high-risk MM patients, which was increased with disease progression and poor prognosis.
PLP2 was increasing in parallel with high beta-2 microglobulin (β2-MG) and lactate dehydrogenase (LDH).
Furthermore, MM patients with low PLP2 expression could achieve a favorable treatment response.
PLP2 may be a novel biomarker for prognostic prediction and a therapeutic target for anti-MM treatments.
American Psychological Association (APA)
Bai, Hua& Zhu, Yudi& Xu, Peipei& Chen, Bing. 2020. PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma. BioMed Research International،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1133864
Modern Language Association (MLA)
Bai, Hua…[et al.]. PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma. BioMed Research International No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1133864
American Medical Association (AMA)
Bai, Hua& Zhu, Yudi& Xu, Peipei& Chen, Bing. PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma. BioMed Research International. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1133864
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1133864